Skip to main content

and
  1. Article

    Open Access

    Clinical efficacy, safety and tolerability of Aliskiren Monotherapy (AM): an umbrella review of systematic reviews

    Aliskiren is a newly developed drug. Its role in lowering BP has been recognized. However, the role of aliskiren in treating heart and renal diseases are still controversial.

    Qiyuan Zhao, Jiantong Shen, **gya Lu, Qi Jiang in BMC Cardiovascular Disorders (2020)

  2. Article

    Open Access

    Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies

    The effect of glucagon-like peptide-1(GLP-1) receptor agonists on heart failure remains uncertain. We therefore conducted a systematic review to assess the possible impact of GLP-1 agonists on heart failure or...

    Ling Li, Sheyu Li, Jiali Liu, Ke Deng, Jason W. Busse in BMC Cardiovascular Disorders (2016)